Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

Har­bin­ger Health, a start­up with am­bi­tious goals to de­vel­op liq­uid biop­sies that spot signs of can­cer ear­ly, has raised $140 mil­lion in Se­ries B fund­ing and an­nounced plans to be­gin sell­ing its first com­mer­cial blood tests in 2025.

The Cam­bridge, MA-based com­pa­ny, which was launched by Flag­ship Pi­o­neer­ing with $50 mil­lion in 2021, has re­mained tight-lipped about ex­act­ly how its ex­per­i­men­tal test works. But Har­bin­ger be­lieves it can get the cost rough­ly an or­der of mag­ni­tude cheap­er than its com­pe­ti­tion, po­ten­tial­ly plac­ing its price tag un­der $100.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER